ImmunoPrecise Antibodies acquires BioStrand

Enlarge

Selena Lu, Eric Lavallée, Serge Shahinian, Sébastien Vézina, Catherine Méthot, Marie-Claude Côté, Mylène Vallières, Siddhartha Borissov-Beausoleil and Jean-Paul Timothée. Source: Lavery website

Immune Precise Antibodies, a biotherapeutics company based in Victoria, British Columbia, confirmed last month the acquisition of BioStrand BV, BioKey BV, and BioClue BV (together, BioStrand), a recognized group of Belgian entities in the field of bioinformatics and biotechnology.

This transaction, which amounts to 20 million euros, or 27 million CA dollars, should allow the Canadian company to exploit the methodology developed by BioStrand from artificial intelligence, and which makes it possible to accelerate the development of therapeutic antibody solutions.

With this technology in hand, IPA hopes to conquer new markets and consolidate its place in the field of biotherapeutics.

Tom Vantroyen and Jef Sprengers.  Sources: Altius website and LinkedIn

Enlarge

Tom Vantroyen and Jef Sprengers. Sources: Altius website and LinkedIn

IPA was represented in this transaction by the firm Lavery. The team, which was led by Selena Lu (transactional), brought together Eric Lavallee (technology and intellectual property), Serge Shahinian (intellectual property), Sebastien Vezina (securities), Catherine Methot (transactional), John Paul Timothy (transferable and transactional securities), Siddhartha Borissov-Beausoleil (transactional), Mylene Vallieres (securities) and Marie-Claude Cote (securities).

For the local aspect of the transaction linked to Belgian law, Lavery was accompanied by Tom Vantroyen and jef sprengersfrom Altius.

Willem Witters and Riet Devriendt.  Source: International law firm Stibbe website

Enlarge

Willem Witters and Riet Devriendt. Source: International law firm Stibbe website

The BioStrand group was represented by willem witters and Riet Devriendtfrom the international law firm Stibbe.

ImmunoPrecise Antibodies is a biotherapeutics company that supports its commercial partners in their research to discover new antibodies against a range of target classes and diseases.

.

Leave a Comment